Understanding Revlimid® (lenalidomide)

couple on bench

Revlimid® (lenalidomide) is an immunomodulatory drug that inhibits new blood vessel development on which cancer cells depend for sustenance and growth. Revlimid is the first oral medication that was developed for treatment of myeloma, and it is used in the newly diagnosed and relapsed and/or refractory settings.

Updated April 28, 2021

Source URL: https://www.myeloma.org/resource-library/understanding-revlimidr-lenalidomide